The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Savolitinib plus gefitinib may have clinical efficacy and a favorable safety profile for patients with EGFR-mutant, MET-amplified non–small cell lung cancer (NSCLC) who progress after EGFR-TKI treatment, according to a study presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Japan.1

For this open-label, phase 1b study (ClinicalTrials.gov Identifier: NCT02374645), researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients (aged 18 years and older; median age 61 years), of whom 6 were T790M-positive and 5 were T790M-negative. Patients underwent central screenings for MET-amplification and evaluations of EGFR. Forty-six percent of patients were still receiving study treatment at the 3-month assessment.

Eleven (25%) patients had confirmed partial responses of anti-tumor activity; 4 patients are awaiting confirmation of response.

The most frequently reported adverse events (AEs) were vomiting (41%), nausea (39%), rash (36%), elevated ALT levels (32%), elevated AST levels (30%), hypoalbuminaemia (25%), gamma-glutamyl transpeptidase increase (25%), and elevation of blood alkaline phosphatase (21%). Grade 3 or worse AEs were reported in 32% of patients.

Related Articles

There were 3 deaths due to AEs but none were considered treatment-related.

The authors concluded that “these encouraging findings warrant further assessment of savolitinib plus gefitinib for patients with EGFR-mutant, MET-amplified NSCLC who progressed on prior EGFR-TKI.”

Read more of Cancer Therapy Advisor‘s coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Yang JJ, Fang J, Shu Y, et al. A phase Ib trial of savolitinib plus gefitinib for chinese patients with EGFR-mutant MET-amplified advanced NSCLC. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan. Abstract OA 09.06.